HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)



Status:Completed
Conditions:HIV / AIDS, HIV / AIDS, HIV / AIDS, Psychiatric, Psychiatric, Gastrointestinal
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases, Psychiatry / Psychology
Healthy:No
Age Range:18 - Any
Updated:7/13/2018
Start Date:June 23, 2014
End Date:June 30, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Project STRIDE2 - Seek/Test/Retain: PLWHA and Opioid Users in Washington, DC

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are
dependent on opioids. This study is funded by the National Institute on Drug Abuse
(R01DA030768, Altice, PI; Taxman & Lawson, Co-PIs) and is being conducted by George Mason
University, Yale University, and Howard University.

STRIDE2 will assist in identifying and monitoring individuals' HIV risk behaviors and provide
resources to seek treatment for their HIV care and substance use. The goal of STRIDE2 is to
examine if there are differences in HIV, drug use, and other outcomes between individuals
receiving treatment versus individuals actively using, not actively using and not in
treatment, and individuals on Methadone, Suboxone, or in some other treatment.

Inclusion Criteria:

1. HIV+, confirmed by rapid HIV test

2. Meet DSM-IV criteria for opioid dependence

3. 18 years or older

4. Have health insurance that is accepted at Lab Corp.

Exclusion Criteria:

1. Are <18 years old;

2. Are HIV negative;

3. Are Unable to communicate in English;

4. Are not able to provide informed consent;

5. Do not meet DSM-IV criteria for opioid dependence;

6. Plan to leave the DC area
We found this trial at
1
site
Howard University
Washington, District of Columbia 20060
?
mi
from
Washington,
Click here to add this to my saved trials